BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 14, 2016, at 11:00 a.m. Pacific Time.
